Autopsy report · NCT00865579

Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients

“study terminated early due to change in Sponsorship”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 3 years 2 months before it stopped.
• 964 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Newron Pharmaceuticals SPA

Sponsor type

Industry

Conditions

Parkinson's Disease

Interventions

Safinamide

Participants

964

Sites

1

Countries

Romania

Trials that died the same way

• Advanced MRI Applications for Mild Traumatic Brain Injury
  “Sponsor terminated early as moving to a new larger study program” (88% match in meaning)
• Visual Function Tests in Age-related Macular Degeneration
  “Study terminated by Sponsor” (88% match in meaning)
• Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria
  “Sponsor terminated study” (87% match in meaning)
• Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients
  “Study terminated by the Sponsor” (86% match in meaning)
• Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors
  “Sponsor decided to terminate study early” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.